<DOC>
	<DOCNO>NCT00621270</DOCNO>
	<brief_summary>The purpose study determine whether BCI-540 80 mg give daily ( q.d . ) three time daily ( t.i.d . ) effective treatment major depression concomitant anxiety .</brief_summary>
	<brief_title>Safety Effectiveness Study BCI-540 Versus Placebo Treatment Major Depressive Disorder With Concomitant Anxiety</brief_title>
	<detailed_description>BCI-540 show neurogenic Sponsor 's vitro neural stem cell analyse vivo animal model depression anxiety . These observation recent finding link hippocampal function neurogenesis mood disorder support evaluation efficacy , safety , tolerability BCI-540 patient major depressive disorder concomitant anxiety .</detailed_description>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Anxiety Disorders</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder , Major</mesh_term>
	<criteria>The patient meet DSM IVTR criterion Major Depressive Disorder ( MDD ) determine MiniInternational Neuropsychiatric Interview ( MINI ) psychiatric evaluation . The patient score 20 HAM D17 scale , score 30 IDSC30 score 15 HAMA scale Screening Baseline visit . The patient score least 2 item 1 2 HAMA scale Screening Baseline visit . The patient Clinical Global Impression Severity ( CGI S ) rating 4 high Screening Baseline visit . The patient recurrent MDD . The patient respond least one five adequate antidepressant trial current MDD episode . The patient live another adult daily contact adult contact information patient adult available investigator . Female patient childbearing potential must use reliable , medically acceptable form contraception least 30 day prior screen visit must agree continue use throughout duration study 30 day final dose study drug . The patient decrease 20 % HAM D17 total score HAMA total score screen visit Baseline visit . The patient represent significant risk suicide opinion investigator screen Baseline visit . The patient psychiatric AxisI disorder ( except GAD ) principal diagnosis within 6 month Screening . The patient history obsessive compulsive disorder , psychotic disorder , bipolar disorder , mental retardation . The patient history alcohol substance ( exclude nicotine caffeine ) abuse within 3 month screen visit , alcohol substance dependence within 6 month Screening . The patient show current evidence substance abuse confirm result urine drug screen . The patient use antidepressant medication ( SSRI/SNRI antidepressant medication , include MAOIs ) , within 1 week Baseline ( fluoxetine within 5 week ) . The patient history low RBC count , low hemoglobin , low WBC count , low platelet , low reticulocyte count aetiology know related blood loss , iron deficiency , pregnancy . The patient show current evidence macrocytosis , low RBC count , low haemoglobin , low WBC count , low platelet count aetiology . The patient use drug study ( include followup ) know related agranulocytosis and/or aplastic anaemia . The patient receive interpersonal therapy and/or shortterm ( brief ) dynamic therapy study . The patient receive ECT within 3 month Screening . The patient receive depot antipsychotic therapy time . The patient use antipsychotic anxiolytic medication within 1 week Screening . The patient use drug know psychotropic property nonpsychotropic drug potential CNS effect within one week 5half life ( whichever longer ) Screening . The patient clinically significant cardiovascular , endocrine , hepatic , renal , pulmonary , gastrointestinal , neurological , malignancy , metabolic , psychiatric condition might detrimental patient participates study . The patient know hypersensitivity cholinesterase inhibitor cholinergic agonist drug . The patient pregnant lactate woman . The patient history seizure . The patient clinically significant abnormality screen physical examination , ECG , serum chemistry , urinalysis test , include thyroid stimulate hormone level , judge investigator . The patient know positivity human immunodeficiency virus , hepatitis B surfaceantigen , hepatitis C virus antibody .</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>October 2011</verification_date>
	<keyword>Major Depression Neurogenesis</keyword>
	<keyword>Major Depressive Disorder Concomitant Anxiety</keyword>
</DOC>